CD209 and cancer: In summary, these data suggested that the particular distribution of CD209, an alternative receptor of SARS-CoV-2 (Amraei et al., 2021), in different cell types might lead to different prognoses in specific carcinoma patients, indicating that during the COVID-19 epidemic, intensive health care is needed for these cancer patients.